Helius Medical Price, Forecast, Insider, Ratings, Fundamentals & Signals

-- helius medical and shepherd center partner on a study that aims at rehabilitating walking mobility in people recovering from stroke -- -- shepherd center, a top neurorehabilitation hospital, is the third site in helius' u.s. registrational program for portable neuromodulation stimulator (pons®) in stroke -- -- the single-arm study will evaluate pons in treating gait and balance deficits in chronic stroke survivors -- -- regulatory submission seeking marketing authorization for stroke expected in 2025-- newtown, pa., april 24, 2024 (globe newswire) -- helius medical technologies, inc. (nasdaq:hsdt) (“helius” or the “company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the expansion of its clinical development program for the broadening of the labeling of its marketed pons device to include patients recovering from stroke with the participation of shepherd center, under the direction of michael yochelson, m...

-- lovell is an approved supplier to the u.s. department of veterans affairs (va) and department of defense (dod) -- -- over 28,000 cases of multiple sclerosis (ms) are reported to the va annually -- newtown, pa., april 03, 2024 (globe newswire) -- helius medical technologies, inc. (nasdaq:hsdt) (“helius” or the “company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced it has partnered with lovell government services (“lovell”), an sba-certified service disabled veteran owned small business (“sdvosb”), to make the company's portable neuromodulation stimulator (“pons®”) device available to federal healthcare systems...

-- company to host call at 4:30pm today -- newtown, pa., march 28, 2024 (globe newswire) -- helius medical technologies, inc. (nasdaq:hsdt) (“helius” or the “company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended december 31, 2023.

Newtown, pa., march 15, 2024 (globe newswire) -- helius medical technologies, inc. (nasdaq: hsdt) (“helius” or the “company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the company will release its fourth quarter and full year 2023 financial results on thursday, march 28, 2024, after the market closes.

-- enrollment of at least ten patients at brooks rehabilitation will begin this month -- -- study will evaluate the use of portable neuromodulation stimulator (pons®) for gait and balance deficits in chronic stroke survivors -- -- results will support efforts to achieve u.s. authorization under pons's breakthrough designation for stroke -- newtown, pa., march 12, 2024 (globe newswire) -- helius medical technologies, inc. (nasdaq:hsdt) (“helius” or the “company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the initiation of an open-label study for its registrational program in stroke. the program was established based on encouraging early trial results as well as real-world evidence from canada, where pons is already authorized for treatment of stroke, and aims to establish the effects of cranial-nerve non-invasive neuromodulation (“cn-ninm”), delivered using pons therapy®, on gait and dynamic balance in chronic stroke survivors.

Helius Medical Technologies, Inc. (HSDT) Q4 2023 Earnings Call Transcript

NEWTOWN, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its fourth quarter and full year 2023 financial results on Thursday, March 28, 2024, after the market closes.

NEWTOWN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at the 36th Annual ROTH Conference, March 17-19, 2024, Laguna Nigel, CA, as follows:

NEWTOWN, Pa., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Dane Andreeff, President and Chief Executive Officer, will present at the NobleCon 19th Annual Emerging Growth Equity Conference as follows:

Helius Medical Technologies, Inc (NASDAQ:HSDT ) Q3 2023 Earnings Call Transcript November 9, 2023 4:30 PM ET Company Participants Michelle Gable Bilski - In-Site Communications, IR Dane Andreeff - President and CEO Jeffrey Mathiesen - CFO Conference Call Participants Nicholas Sherwood - Maxim Group Jonathan Aschoff - ROTH MKM Operator Good day, everyone. My name is Chelsea, and I will be your conference operator.

-- Expects to report Q3 revenues in range of $140 - $150 thousand, reflecting the expected decrease in U.S. sales with the conclusion of the Patient Therapy Access Program (PTAP) on June 30, 2023 -- -- Expects to report approximately $7.0 million in cash, cash equivalents and proceeds receivable from warrant exercises, extending cash runway into Q2 2024 -- -- Expects to report cash used in operating activities for the first nine months of 2023 ranging from $8.3 - $8.4 million, and for Q3 $2.4 - $2.5 million, reflecting continued focus on cash management --

In September, sales at U.S. retailers defied expectations by increasing 0.7%, demonstrating that households possess substantial purchasing power, a crucial factor in sustaining economic growth. A surge in demand at auto dealerships and online stores fueled this robust upswing.

-- Presentation to educate on Portable Neuromodulation Stimulator (PoNS®) Therapy, highlighting the differentiation from other neuromodulation technologies, and the science behind its effectiveness, clinical data, safety profile -- -- Forum brings together world experts from the core disciplines of clinical neurosciences and rehabilitation --

Helius Medical Technologies (NASDAQ: HSDT ) stock is rising higher on Tuesday as investors react to the neurotechnology company regaining listing compliance. Helius Medical Technologies says that it is no longer in danger of having its stock delisted in an investor update.

Helius Medical Technologies, Inc. (NASDAQ:HSDT ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Michelle Bilski - In-Site Communications, IR Dane Andreeff - President and CEO Jeff Mathiesen - CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Destiny Buch - Ladenburg Thalmann & Co. Anthony Vendetti - Maxim Group Operator Good day, and thank you for standing by. Welcome to the Helius Medical Technologies, Inc. Q2 2023 Earnings Conference Call.